ProMIS Neurosciences Inc (NAS:PMN)
$ 0.9 -0.0124 (-1.36%) Market Cap: 29.42 Mil Enterprise Value: 8.26 Mil PE Ratio: 0 PB Ratio: 4.09 GF Score: 35/100

ProMIS Neurosciences Inc at HC Wainwright Investment Conference - New York Transcript

Sep 12, 2023 / 08:30PM GMT
Release Date Price: $1.99 (+5.85%)
Ananda Ghosh
H.C. Wainwright & Co., LLC - Analyst

Hi, good afternoon, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Ananda Ghosh, an associate at H.C. Wainwright. That said, I would like to welcome Gail Farfel, CEO of ProMIS Neurosciences; and Larry Altstiel, CMO of ProMIS Neurosciences.

Larry Altstiel
ProMIS Neurosciences Inc. - Chief Medical Officer

Thank you.

Gail Farfel
ProMIS Neurosciences Inc. - CEO & Director

Thank you, Anand. It's a pleasure to be here, and we thank the organizers for inviting us. My disclosures -- or our disclosures are contained here. ProMIS Neurosciences is a company developing next-generation antibodies for treatment of neurodegenerative diseases. We have a proprietary platform, a computational algorithm that allows us to predict how proteins can misfold and then design antibodies -- generate antibodies specific to toxic misfolded forms of these proteins.

Our lead compound, our lead candidate is PMN310,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot